ClinicalTrials.Veeva

Menu

Ioflupane I123 (DaTSCAN) and Positron Emission Tomography-computed Tomography Fludeoxyglucose (PET-CT FDG) to Assess Brain Function of Parkinson Patients' First Degree Relatives

T

Tel Aviv Sourasky Medical Center

Status

Unknown

Conditions

Parkinson Disease

Study type

Observational

Funder types

Other

Identifiers

NCT01089270
TASMC-10-EES-0519-CTIL

Details and patient eligibility

About

Parkinson Disease is one of the most common neurodegenerative illnesses. First degree relatives of Parkinson patient are in high risk for developing the disease. We will try to detect early changes in brain metabolism before the appearance of Parkinson symptoms.

Participants: first degree relatives of diagnosed Parkinson patients that carry a gene mutation in either LRRK2 or GBA genes.

The examination results will be given to the participants by a doctor from the neurology department.

Enrollment

80 estimated patients

Sex

All

Ages

30 to 80 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • healthy first degree relatives of diagnosed Parkinson patients

Exclusion criteria

  • patients unable to understand and sign an informed consent
  • minors
  • people with psychiatric disorders or a history of major head trauma

Trial contacts and locations

1

Loading...

Central trial contact

Einat Even-sapir, PhD, MD; Ayelet Kurzband, BA

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems